Welcome to our dedicated page for Inspiremd SEC filings (Ticker: NSPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
InspireMD filings document regulatory disclosures for a Nasdaq-listed medical device company focused on CGuard carotid stent systems and related neuro protection technology. Recent Form 8-K reports cover operating and financial results, Regulation FD materials, FDA IDE and product-recall disclosures, capital-raising arrangements under an at-the-market equity distribution agreement, and executive employment matters.
Proxy materials describe annual meeting voting items, board and compensation governance, and stockholder procedures. Registration-statement references and capital-structure disclosures identify common stock, shelf registration mechanics, offering terms, and Nasdaq Capital Market listing information.
InspireMD, Inc. reported results of its 2026 annual stockholder meeting. Stockholders approved an amendment to the Amended and Restated Certificate of Incorporation increasing authorized common shares from 150,000,000 to 250,000,000, effective upon filing a Certificate of Amendment in Delaware on June 3, 2026.
As of April 10, 2026, there were 46,892,979 common shares outstanding, and 34,631,348 shares, or 73.85%, were present in person or by proxy, constituting a quorum. Stockholders re-elected Marvin Slosman, Raymond Cohen and Dan Dearen as Class 3 directors for three-year terms, approved the authorized share increase, and ratified Kesselman & Kesselman, a member of PricewaterhouseCoopers International Limited, as independent registered public accounting firm for the 2026 fiscal year.
InspireMD director Paul Stuka reported an open-market purchase of 20,000 shares of InspireMD, Inc. common stock on May 27, 2026 at $0.875 per share. Following this transaction, he directly holds 667,871 shares. Separately, 423,704 shares are held indirectly through Osiris Investment Partners, L.P., with no new transaction reported for those indirectly held shares.
InspireMD, Inc. reported that Board Chair Paul Stuka has decided not to seek reelection as a Class I director at the company’s 2027 Annual Meeting of Stockholders and plans to retire from the Board at that time.
The company states that his decision does not result from any disagreement regarding operations, policies, or practices. Stuka currently serves as Chair of the Board, Chair of the Compensation Committee, and as a member of the Audit and Nominating and Corporate Governance Committees, and he expects to continue in these roles until his term expires. The Nominating and Corporate Governance Committee plans to identify and evaluate suitable candidates as part of Board succession planning.
InspireMD, Inc.’s Chief Commercial Officer Shane Thomas Gleason reported a series of open-market sales of common stock primarily to cover tax withholding on vested restricted stock. The latest transaction on May 19, 2026 involved selling 22,778 shares at a weighted average price of $1.01 per share.
The filing shows a total of 85,295 shares sold across 14 transactions since early 2025, all described as required sales under an automatic sales instruction letter effecting a sell-to-cover election. Following the most recent sale, Gleason directly holds 1,053,882 shares of InspireMD common stock.
InspireMD, Inc. amendment discloses that Nantahala Capital Management, LLC and its principals beneficially own 4,819,647 shares of common stock, representing 9.99% of the class as of March 31, 2026. The disclosed holdings include 1,443,163 shares that may be acquired within sixty days through the exercise of convertible securities.
The filing states that Nantahala holds these shares on behalf of funds and separately managed accounts and that Messrs. Wilmot B. Harkey and Daniel Mack are control persons with shared voting and dispositive power over the same block.
InspireMD, Inc. director Paul Stuka reported open-market purchases of the company’s common stock. He bought 10,000 shares on May 13, 2026 at $1.1575 per share and 5,000 shares on May 14, 2026 at $1.1500 per share, for a total of 15,000 shares.
After these direct purchases, he directly owned 647,871 shares. An additional 423,704 shares are held indirectly through Osiris Investment Partners, L.P.; the filing states no transaction occurred in those indirect holdings and that they are included for informational purposes, with beneficial ownership disclaimed except for any pecuniary interest.
InspireMD, Inc. ownership disclosure: Velan Capital Master Fund and related Velan entities report beneficial ownership of 2,347,779 shares of Common Stock, representing approximately 4.99% of the outstanding shares.
The filing states the shares outstanding were 46,801,561 as of March 18, 2026. The report also lists Warrants exercisable into 452,015 Series J, 452,014 Series K and 904,029 Pre-funded shares, each subject to 4.99% beneficial ownership limitations; certain warrant issuable amounts are excluded from the reported ownership due to those limits.
InspireMD, Inc. CEO and President Marvin Slosman reported an open-market purchase of 21,000 shares of Common Stock at $1.20 per share. Following this transaction, he directly owns 3,556,658 InspireMD shares, indicating a modest increase in his personal stake in the company.
InspireMD, Inc. director Paul Stuka reported open-market purchases of 75,626 shares of Common Stock. He bought 65,626 shares on May 8, 2026 at a weighted average price between $1.15 and $1.16, and 10,000 shares on May 11, 2026 at a weighted average price between $1.17 and $1.20.
Following these purchases, he directly beneficially owned 632,871 shares and indirectly, through Osiris Investment Partners, L.P., beneficially owned 423,704 shares. The amendment also corrects earlier reports by confirming certain shares were held directly rather than indirectly and states that these corrections did not change his pecuniary interest. It further clarifies that the transactions were not effected under a Rule 10b5-1(c) trading plan and that the Osiris-held shares are included here for informational purposes only.
InspireMD, Inc. director Paul Stuka reported open-market purchases of the company’s common stock. On May 8, 2026, he bought 65,626 shares at a weighted average price of $1.16 per share, followed by another 10,000 shares on May 11, 2026 at a weighted average price of $1.19 per share.
After these transactions, Stuka directly beneficially owned 632,871 shares of InspireMD common stock. Footnotes state that, immediately before these trades, he directly owned 557,245 shares and indirectly, through Osiris Investment Partners, L.P., beneficially owned 423,704 shares. The Osiris-held shares are reported for informational purposes, with Stuka disclaiming beneficial ownership except to the extent of his pecuniary interest.